Preparation and preclinical evaluation of radioiodinated secnidazole as a possible tumor imaging agent


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

To develop a radiopharmaceutical localizing in tumor hypoxic tissues, secnidazole (SECN) was labeled with 125I. The labeled product was prepared with the radiochemical yield higher than 96% when performing the reaction at 45°C for 30 min. The electrophilic radioiodination of SECN was done using different oxidizing agents. Iodogen appeared to be more effective than chloramine-T (CAT) and N-bromosuccinimide (NBS). 125I-SECN was tested in vivo with a tumor model prepared by the intramuscular injection of Ehrlich cell line into the thigh muscle of mice. 125I-SECN showed high accumulation in tumor hypoxic tissue (3.6% of injected dose per gram of organ at 2 h post injection). The target/nontarget (T/NT) ratio was high (T/NT = 6 at 24 h post injection). Thus, radioiodinated SECN shows promise as a selective imaging agent for diagnosis of tumor hypoxia.

作者简介

A. Amin

Hot Laboratories Centre

Email: ab_amin@hotmail.com
埃及, Cairo

I. Ibrahim

Hot Laboratories Centre

编辑信件的主要联系方式.
Email: ab_amin@hotmail.com
埃及, Cairo

S. Abd Elhalim

Hot Laboratories Centre

Email: ab_amin@hotmail.com
埃及, Cairo

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Inc., 2017